Defunct Company
Total Trials
4
As Lead Sponsor
0
As Collaborator
Total Enrollment
185
NCT02499835
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
Phase: Phase 1/2
Role: Collaborator
Start: Jul 1, 2015
Completion: Jul 27, 2023
NCT02411786
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
Phase: Phase 1
Start: Aug 24, 2015
Completion: Nov 28, 2020
NCT03600350
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
Phase: Phase 2
Start: Sep 10, 2018
Completion: Dec 31, 2027
NCT04090528
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Start: Oct 21, 2019
Completion: Oct 31, 2026